Ripple Therapeutics Corporation, a clinical stage, ophthalmology-focused developer of novel pharmaceuticals, announced, on April 20, that the first patient has been treated in RIPPLE-1, a Phase II trial evaluating IBE-814 IVT, a proprietary intravitreal dexamethasone implant targeting inflammatory retinal diseases.